Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference
10 nov. 2021 11h50 HE
|
Athira Pharma, Inc.
– Balanced baseline characteristics in ACT-AD and LIFT-AD to date –– Topline data from ACT-AD trial targeted for first half of 2022 – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira...